Skip to main content

Lanxess buys Brazilian biocide maker, exits Currenta

3rd December 2019

Submitted by:

Andrew Warmington

Lanxess has agreed to acquire Itibanyl Produtos Especiais (IPEL), a family-owned company based at Jarinu, São Paulo. Terms were not disclosed and the deal should be completed in Q1 2020, subject to regularly approvals.

IPEL is said to be one of Brazil’s leading biocide manufacturers and generated sales in the lower double-digit million euro range in 2018, mostly in biocides. It employs around 100 people and has both laboratory and manufacturing facilities.

This gives Lanxess’s Material Protection Products business unit a manufacturing presence on four continents, as well as access to strategic intermediate products. “IPEL also has a strong customer network that will soon be able to benefit from our combined product portfolio and regulatory expertise,” added Oliver Kretschik, head of the Biocides business line.

Separately, Lanxess has completed the sale of its 40% stake in chemical park operator and site services provider Currenta to funds managed by Australia-based Macquarie Infrastructure & Real Assets (MIRA). The former owner, Bayer, has simultaneously sold its 60% share. Lanxess’s take was given a pre-tax equity value of €780 million.

Currenta manages the chemical parks in Leverkusen, Dormagen and Krefeld-Uerdingen, Germany. The sale, which was agreed in August, came about because Bayer announced plans to exit Currenta in November 2018 and neither Lanxess nor Covestro wanted to take over any of its share.

Lanxess expects retain its share in the park operator until April next year and will give operational support to MIRA during the transitional phase while receiving a share of the profits. CEO Matthias Zachert added that the sale will give Lanxess “additional leeway to drive forward our growth course in speciality chemicals”.

UPL to split out specialities

Indian agrochemicals giant UPL has announced plans to transfer its speciality chemicals business, including agrochemical

Submitted by:

Andrew Warmington

AI for SAPs

Together with Algo Artis, Japan’s Nippon Shokubai has developed an algorithm-based means for the production

Submitted by:

Andrew Warmington

Nippon Shokubai's API Facility in Japan

Nucleic acid API boost

Nippon Shokubai is to expand its GMP capacity for nucleic APIs tenfold It will install

Submitted by:

Andrew Warmington

Flamma's facility in Dalian

Flamma opens in China

Italian CDMO Flamma Group has officially opened its new cGMP plant at Dalian, China, where

Submitted by:

Andrew Warmington

GL Chemtec has opened a new kilo lab

GL Chemtec completes kilo lab

CDMO GL Chemtec has announced the completion of a cGMP kilo lab at Oakville, Ontario

Submitted by:

Andrew Warmington

Sterling's facility at Deeside, UK

CDMOs in ADC investments

Five CDMOs across the world have separately announced investments in antibody-drug conjugates (ADCs). Piramal Pharma is

Submitted by:

Andrew Warmington

Halozyme has dropped its approach to buy Evotec

Halozyme abandons Evotec bid

San Diego-based biopharmaceutical company Halozyme Therapeutics has withdrawn the offer it made for Evotec after

Submitted by:

Andrew Warmington

Afyren Neoxy plant

Milestones for two greentech firms

Afyren has achieved continuous production at its Afyren Neoxy plant at Clermont-Ferrand (pictured)

Submitted by:

Andrew Warmington

Origin by Ocean derives its materials from sargassum

CABB in algae biorefinery deal

CABB has agreed a strategic partnership to establish a first-in-kind algae biorefinery at its site at Kokkola

Submitted by:

Andrew Warmington

First waste-based biosurfactants

Belgian start-up AmphiStar has launched what it claims are the first fully upcycled biobased surfactants

Submitted by:

Andrew Warmington

Aether to supply Seqens

Indian firm Aether Industries has entered into a manufacturing agreement with Chemoxy International, a UK-based

Submitted by:

Andrew Warmington

New model for biocatalysts

BASF, the Austrian Research Centre of Industrial Biotechnology (ACIB) and the University of Graz in

Submitted by:

Andrew Warmington

CBE JU funds 31 more projects

The Circular Bio-based Europe Joint Undertaking (CBE JU), a €2 billion partnership between the EU

Submitted by:

Andrew Warmington

Ribbon cutting ceremony at Lubrizol's new office

Lubrizol opens London office

Lubrizol has opened a new office in Hammersmith, London. This will be home to a

Submitted by:

Andrew Warmington

Sudarshan to buy Heubach

India’s Sudarshan Chemical Industries (SCIL) has entered into a definitive agreement to acquire the Heubach

Submitted by:

Andrew Warmington

Alliance in natural fragrances

Sensegen, a US-based specialist in biotech-enabled fragrances, notably a new class of natural musk raw

Submitted by:

Andrew Warmington

Croda breaks ground in China

Croda International has broken ground for a low-carbon, multi-purpose production facility on a greenfield site

Submitted by:

Andrew Warmington

CCT collaboration for Givaudan

Flavours and fragrances giant Givaudan has agreed a research collaboration for the development of sustainable

Submitted by:

Andrew Warmington

REACH Authorisation

Candidate List ‘reaches’ 250

The European Chemicals Agency (ECHA) has added three more substances to the Candidate List of

Submitted by:

Andrew Warmington

Staff at Brenntag's newly acquired Czech site

CO2-free distribution site first

Brenntag has officially inaugurated what it claims to be the first CO2-emission-free chemical distribution site

Submitted by:

Andrew Warmington